On 13th May, 2022, Nepal’s population will cast their votes for the local elections. During 2022, Nepal’s voters will determine the future of their country by voting in local, provisional and national elections.
This is Nepal’s second local level election since the introduction of the Nepalese Constitution in 2015. Many voters await Friday with great enthusiasm to exercise their political rights.
Across the world, many developing countries such as Nepal have a population of people who struggle to access essential healthcare services. This often leads to an increase in poverty and unemployment. The Tej Kohli and Ruit Foundation are here to change that.
The number one United Nations Sustainable Development Goal (SGD1) is to end extreme poverty everywhere. A little-known fact is that needless blindness is a cause and is also a consequence of extreme poverty. That’s why Tej Kohli and Dr Sanduk Ruit are making large-scale treatment interventions to cure blindness in the poorest communities of the developing world.
MIOK Keratoprosthesis has been approved for listing by National Medical Products Administration (NMPA), the Chinese agency for regulating drugs and medical devices. MIOK Keratoprosthesis is the world’s first-ever approved artificial cornea that requires no co-implantation of donor corneas, and is of great significance across the 60 million patients with corneal blindness worldwide, as MIOK Keratoprosthesis makes it no longer impossible to restore sight to patients with corneal blindness, and ease the burden on their families.
Developed by Beijing Microkpro Medical Instrument, MIOK Keratoprosthesis is mainly made of clear PMMA plastic with excellent optical properties and tissue tolerance, and it is intended to restore sight to patients with corneal blindness by providing a transparent optical pathway through an opacified cornea in the treated eye.
Newswise — A patented biomaterial developed by South Dakota State University associate professor Gudiseva Chandrasekher has the potential to repair corneal damage and to create corneal implants. Chandrasekher been doing research on corneal tissue in the Department of Pharmaceutical Sciences since 2008.
This spring, he will begin a two-year research project through the Drug, Disease and Delivery Center to determine whether the patented biomaterial can be used to construct corneal implants. The SDSU-led 3D Center recently received a five-year, $3.9 million award from the South Dakota Research and Commercialization Council.
It took Parasa Thapa a lot of courage to embark on a journey into the unknown with just one hundred Nepalese rupees in her pocket. That small amount of change — about $1.35 — was all of the money that Parasa had to her name. But as a mother, she knew that she needed to do something to help her two young daughters, who were both slowly going blind.
